Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA). The company’s Sirolimus tablets in 1 mg and 2 mg are available in bottle counts of 100.

According to IMS Health, the RAPAMUNE tablets brand had US sales of approximately $206 million MAT for the most recent twelve months ending in August 2014.

Dr. Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.